Agomab’s Fibrosis Pipeline Gets $100M Boost in Series C Funding

Agomab Therapeutics NV secures $100 million Series C funding to advance the STENOVA Phase 2a clinical trial for AGMB-129, a gut-specific ALK5 inhibitor targeting Fibrostenosing Crohn’s Disease (FSCD). Fidelity Management & Research Company led the round with notable participation from EQT Life Sciences, Canaan, and Dawn Biopharma.

Agomab Therapeutics applies profound expertise in growth factor biology to develop novel treatments targeting fibrosis. Their approach combines cutting-edge scientific insights with strong drug development strategies. AGMB-129 was granted U.S. FDA Fast Track designation. FSCD significantly impacts Crohn’s Disease patients, causing fibrotic strictures and surgeries, yet lacks approved treatments. Positive Phase 1 results confirm AGMB-129’s safety and gastrointestinal (GI)-specific exposure, marking a significant step in Agomab’s fight against FSCD.

The Series C funding for Agomab Therapeutics NV will advance clinical trials for AGMB-129 and support the development of growth factor-targeting drug candidates like AGMB-447 and AGMB-101/102. It will also aid strategic expansion and essential corporate activities.

Felice Verduyn-van Weegen from EQT joins the Board of Directors, enhancing strategic guidance. Moreover, representatives from Dawn Biopharma and Canaan join as Board Observers, contributing to the company’s growth and development initiatives. The funding reflects a pivotal step in Agomab’s journey to combat fibrosis and related disorders.

Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics said in a statement:

“With the addition of these world-class investors we continue to build the company as a leader in the field of fibrosis and have secured the funding required to conduct clinical studies for multiple drug candidates. I am very pleased to be able to work with the new board to further develop our potentially game-changing therapeutics for the many patients in high need for anti-fibrotic therapies.”